Pancreatic Cancer Metastatic Clinical Trial
Official title:
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine Versus Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Aim：Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Drug information： - anti-PD1 antibody (Camrelizumab) - AG regimens：the standard first-line regimens for metastatic pancreatic cancer.
CPOG1210-07 is a prospective, randomized, double-blinded, multi-center clinical trial in China aiming to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. The anti-PD1 antibody(Camrelizumab) is a humanized monoclonal antibody which can specifically bind to PD-1 and block the interaction between PD-1 and its ligand (PD-L1), allowing T cells to recover the immune response against tumors. It is proved to be effective in certain cancers such as ovarian cancers and certification proved by Chinese Food and Drug Administration(CFDA) includes Hodgkin's lymphoma, non-small cell lung cancer, esophageal cancer and liver cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06155136 -
RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
|
||
| Not yet recruiting |
NCT05047991 -
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
| Completed |
NCT03504423 -
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
|
Phase 3 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04799431 -
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
|
Phase 1 | |
| Completed |
NCT03412799 -
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
|
Phase 1 | |
| Withdrawn |
NCT04852367 -
PanDox: Targeted Doxorubicin in Pancreatic Tumours
|
Phase 1 | |
| Recruiting |
NCT04467593 -
Safety Study of Whole Body Hyperthermia for Advanced Cancer
|
N/A | |
| Recruiting |
NCT02959151 -
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
|
Phase 1/Phase 2 | |
| Completed |
NCT01652976 -
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT04721301 -
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
|
Phase 1 | |
| Recruiting |
NCT04667403 -
Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06168812 -
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06076837 -
The Seven Trial: Exploiting the Unfolded Protein Response
|
Phase 1 | |
| Active, not recruiting |
NCT03984214 -
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05254171 -
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04116073 -
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
|
Phase 2 | |
| Recruiting |
NCT04338763 -
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06030622 -
Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
|
Phase 1/Phase 2 |